Our Correspondent
The Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) that met on January 1 and 2, 2021 has granted the permission to Cadila Healthcare Ltd for conduct of the Phase III clinical trial of the Novel Corona Virus-2019-nCov-Vaccine it has developed.
The firm initiated Phase-I/II clinical trial in India in more than 1,000 participants which is ongoing. The interim data suggests that the vaccine is safe and immunogenic with three doses when administered intradermally. Accordingly, firm has sought permission to conduct Phase-III clinical trial in 26,000 Indian participants, which has been recommended by the Subject Expert Committee.
The approval for the third phase of trials for Cadila Healthcare Ltd came even as the CDSCO approved vaccines of M/s Serum and M/s Bharat Biotech for restricted use in emergency situation.
By Joseph Maliakan Nithin Raj 22, a dalit , son of Latha , a daily…
By Joseph Maliakan You scratch an Indian, the caste comes out , irrespective of whether…
SRUTHI MATHAA… LAYA PITHAA… The International Chamber for Indian Music & Culture, an international initiative…
By Joseph Maliakan The Viksit Bharat Shiksha Adhishthan ( VBSA) ,Bill 2025 to replace the…
Kochi: A prominent NRI who is known for his corporate finance expertise and association with…
By Joseph Maliakan As a reporter who has witnessed the continuous erosion of academic freedoms…
This website uses cookies.